Recent estimates by the World Health Organization (WHO) calculate at least 171 million people worldwide suffer from diabetes and expect this figure to more than double, to reach 366 million, by 2030

According to Sanofi-Aventis SA, its long-acting Lantus [insulin glargine] drug didn't increase the risk of blindness for diabetics compared to an older type of insulin in a five-year study of more than 1,000 patients. In addition, there was...no 'observable trend' showing a difference in the risk of serious side effects including cancer, the drugmaker said in a statement.

"This 5-year study is the longest randomized controlled study with insulin glargine versus NPH human insulin," said lead investigator Julio Rosenstock, MD, Director of the Dallas Diabetes and Endocrine Center at Medical City and also Clinical Professor of Medicine, University of Texas Southwestern Medical Schoo.

The study results were published in the online edition of the Diabetologia medical journal.

Posted in: diabetes, Diabetes mellitus, Sanofi-Aventis, World Health Organization